Aiming to file a biologics license application in 2007, Dynavax Technologies Inc. began a pivotal Phase III trial to test its Toll-like receptor 9 hepatitis B vaccine against the efficacy of Engerix-B, GlaxoSmithKline plc's HBV vaccine, in older adults. (BioWorld Today)